Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Georgia US - United States Signed bill amends state hemp law in significant ways ...
  • Connecticut - United States House bill to amend state cannabis law passes to Senate ...
  • United States DEA and HHS agree on rescheduling of cannabis, now await OMB and public comment ...
  • United Kingdom FSA committee grants first-ever novel food authorisations for two CBD products ...
  • Germany Amendment to Cannabis Act to be discussed and referred to Health Committee ...
  • Switzerland Initiative seeks constitutional amendment to legalise recreational cannabis ...
  • Ukraine Public consultation open on procedure to buy cannabis seeds for medical reasons ...
  • Ukraine Public consultation open on procedure for transportation of narcotics ...
  • Ukraine Public consultation open on regulation on medical cannabis information system ...
  • Ukraine Public consultation open on procedure for selecting cannabis samples for testing ...
  • Germany Associations asked to comment on draft recreational cannabis bill ...
  • North Dakota - United States State secretary approves petition format for cannabis measure ...
View all
News analysis

Italy’s classification of CBD extracts as pharmaceuticals riles cannabis firms

Written by || 6th September 2023 || News analysis | CBD | Regulation and legislation | GeographiesEurope Italy

Cannabis companies in Italy are opposing a government decree which may outlaw CBD oils for oral use in the country.

The decree, which will become effective on 20th September, revokes the suspension of a 2020 decree classifying oral products obtained from cannabis extracts as pharmaceutical substances. Based on the 2020 decree, CBD ingestible products should be treated as prescription drugs.

Read full article

Download the full news analysis

“Italy’s classification of CBD extracts as pharmaceuticals riles cannabis firms”








    I'm already a subscriber

    Login

    Tiziana Cauli

    Senior reporter/health & science editor
    Tiziana is an Italian journalist from Sardinia. She has worked for both international and local media in Italy, South Africa, France, Spain, the UK, Lebanon and Belgium. She also worked as a communications manager for several international NGOs in the humanitarian sector.

    Our Key Benefits

    The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

    CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

    • Stay informed of any legal and market change in the sector that impacts your organisation
    • Maximise resources by getting market and legal data analysis daily in one place
    • Make smart decisions by understanding how the regulatory and market landscape evolves
    • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

    Thanks for getting in touch with us

    Please leave your enquiry and we will get back to you within 24 hours


      Sign up to our newsletter

      Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis


        See more


        By signing up you agree to our Privacy Policy.